Pharmacokinetics Study of MCI-186 in Subjects With Mild or Moderate Hepatic Impairment
Abroad (travel likely)CompletedPHASE1
Conditions
Hepatic Impairment · Healthy
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Investigational site, Fukuoka, Japan
Investigational site, Tokyo, Japan
Study leads
General Manager
Study Director
Tanabe Pharma Corporation
View source on ClinicalTrials.gov(opens in a new tab)
No study contact email or phone is listed for this trial.